Updated:
Cambrex Corporation
Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
Cambrex Corporation
Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey. The company provides contract development and manufacturing services for branded and generic pharmaceutical companies, focusing on small-molecule active pharmaceutical ingredients (APIs). Cambrex operates 14 manufacturing and development sites across North America and Europe. The company's services span drug substance development, analytical testing, and commercial-scale production. It serves a diverse client base ranging from emerging biotechs to top 20 global pharmaceutical firms. As a publicly traded company on the New York Stock Exchange (CBM), Cambrex had approximately 2,300 employees as of 2023. The company has made selective acquisitions to expand capacity and capabilities, including the 2019 purchase of Halo Pharmaceutical to strengthen its oral solid-dose formulation offerings. Cambrex's structural differentiator is its vertically integrated small-molecule CDMO model. Unlike academic spinouts or virtual biotechs, it owns the full manufacturing infrastructure, giving drug developers a single partner for API synthesis through finished dosage forms, reducing supply chain complexity.
General information
Firm type
other
Year founded
1981
AUM
Undisclosed
Location
Region
North America
Country
United States
City
East Rutherford
Corporate office
East Rutherford, NJ, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Cambrex?
As a publicly traded company, strategic and investment decisions at Cambrex are made by its board of directors and executive management team, led by the CEO. The company's public filings with the SEC disclose executive compensation, board composition, and material transactions.
How does Cambrex source proprietary deal flow?
Cambrex's pipeline comes primarily from pharmaceutical companies seeking outsourced manufacturing and development. As a CDMO, it competes for contracts through a business development team and by demonstrating technical capabilities in small-molecule API synthesis.
Is Cambrex structured as a single family office or does it operate more like a venture firm?
Cambrex is a publicly traded contract development and manufacturing organization, not a family office or investment firm. It generates revenue from services, not from investment returns on committed capital.
Does Cambrex participate in fund commitments or only direct deals?
Cambrex is an operating company, not an investor. It does not commit capital to external funds; instead, it finances its own manufacturing capacity expansions and acquisitions through cash flow, debt, and equity markets.
What investment stages does Cambrex typically target?
Cambrex serves drug developers across all stages, from clinical-trial-scale runs to commercial production. Its business model is contracted manufacturing, not investment-stage targeting.
Which sectors does Cambrex explicitly avoid?
Cambrex focuses on small-molecule APIs and oral solid-dosage forms. It does not provide large-molecule biologics manufacturing services, nor does it invest in early-stage biotech companies as a venture partner.
How is Cambrex related to any parent or related vehicle?
Cambrex is an independent publicly traded corporation (NYSE: CBM). It has no single-family-office parent. Its largest institutional shareholders as of 2023 included Vanguard and BlackRock, typical for a public company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: